Skip to Main Content

Universal Public Finance of Tuberculosis Treatment in India: An Extended CEA

2015

This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India using extended cost-effectiveness analysis (ECEA). The authors evaluated the impact of UPF on health gains, financial consequences, and catastrophic health expenditures, and concluded that the health gains and insurance value of UPF would accrue mostly to the poor. However, reductions in out-of-pocket expenditures were found to be more uniformly distributed across income quintiles. A variant on the base case suggests that lowering costs of borrowing for the poor could potentially achieve some of the health gains of UPF, but at the cost of leaving the poor more deeply in debt.

 

Source:

Verguet S, Laxminarayan R, Jamison DT. Universal Public Finance of Tuberculosis Treatment in India: An Extended Cost-Effectiveness Analysis. Health Economics 2015; 24 (3): 318-332. https://doi.org/10.1002/hec.3019